Metrics as of 10/16/2026, 03:37 PM (Berlin time), refresh in progress.
Orchestra BioMed Holdings Stock
Orchestra BioMed Holdings, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- David Hochman
- Employees
- 86
- Market cap
- $347 M
- IPO
- 04/08/2020
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The…
Orchestra BioMed Holdings stock: price history
1D
+1.8%
1W
+0.2%
1M
-5.0%
6M
+28.4%
YTD
+38.3%
1Y
+56.8%
2Y
+7.9%
5Y
-41.7%
10Y
–
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~16% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Orchestra BioMed Holdings
Analyst assessment of Orchestra BioMed Holdings
PRICE TARGET LOW
US$10.00
CONSENSUS
US$10.75
MEDIAN
US$10.00
PRICE TARGET HIGH
US$13.00
0
STRONG BUY
6
BUY
0
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 15/09/2026
Orchestra BioMed Holdings stock metrics
P/E
-5.83
P/B
12.51
EV/EBITDA
-6.95
RETURN ON EQUITY
-80.7%
NET MARGIN
-26,994.3%
DEBT/EQUITY
2.41
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
68.9%
FLOAT SHARES
41,403,038
AVG. DAILY VOLUME (30D)
340,343
Insider transactions (SEC)
Sherman Darren
Hochman David P
Hochman David P
Hochman David P
Sherman Darren
Institutional holders
Comparable stocks
Frequently asked questions about Orchestra BioMed Holdings stock
What does Orchestra BioMed Holdings do?
Orchestra BioMed Holdings, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is David Hochman, the company employs around 86 people.
The IPO was on 04/08/2020; the stock trades on NASDAQ under the ticker OBIO.
What do analysts say about Orchestra BioMed Holdings stock?
6 analysts rate the stock, the consensus is Buy (as of 15/09/2026).
The average price target is US$10.75, ranging from US$10.00 to US$13.00, with a median of US$10.00.
This is an external assessment, not a statement by Market Jury.
When does Orchestra BioMed Holdings report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 16% stronger than usual.
Does Orchestra BioMed Holdings pay a dividend?
No, Orchestra BioMed Holdings currently does not pay a dividend.
Which stocks are comparable to Orchestra BioMed Holdings?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Orchestra BioMed Holdings stock analyzed?
Clicking "Analyze stock" lets five strategies assess Orchestra BioMed Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.